Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients.

ABSTRACT:

Background

Increasing evidence suggests that severe skeletal muscle index (SMI) loss (sarcopenia) is associated with poor overall survival in metastatic colorectal cancer patients, but its mechanisms are unknown. We recently found, using data of the randomized phase 3 CAIRO3 study, that SMI loss was related with shorter time to disease progression and overall survival during first-line maintenance treatment with capecitabine + bevacizumab (CAP-B) or observation and during more intensive capecitabine + oxaliplatin + bevacizumab (CAPOX-B) reintroduction treatment. As a potential risk factor for reduced survival, we explored whether sarcopenia and SMI loss were associated with dose-limiting toxicities (DLTs) during CAP-B and CAPOX-B.

Methods

Sarcopenia status and SMI loss were

SUBMITTER: Kurk S 

PROVIDER: S-EPMC6711417 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature